We are live on ! Find out more
CNMD icon

CONMED

230 hedge funds and large institutions have $2.5B invested in CONMED in 2019 Q2 according to their latest regulatory filings, with 39 funds opening new positions, 78 increasing their positions, 77 reducing their positions, and 32 closing their positions.

New
Increased
Maintained
Reduced
Closed

264% more call options, than puts

Call options by funds: $1.75M | Put options by funds: $479K

22% more first-time investments, than exits

New positions opened: 39 | Existing positions closed: 32

2% more funds holding

Funds holding: 226230 (+4)

3% more capital invested

Capital invested by funds: $2.42B → $2.5B (+$82M)

1% more repeat investments, than reductions

Existing positions increased: 78 | Existing positions reduced: 77

0.22% more ownership

Funds ownership: 103.38%103.6% (+0.22%)

100% less funds holding in top 10

Funds holding in top 10: 10 (-1)

Holders
230
Holders Change
+4
Holders Change %
+1.77%
% of All Funds
4.97%
Holding in Top 10
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
New
39
Increased
78
Reduced
77
Closed
32
Calls
$1.75M
Puts
$479K
Net Calls
+$1.27M
Net Calls Change
+$334K

CNMD Hedge Fund Activity: Q2 2019 in Review

230 of the 4,625 institutional investors tracked by Wall St. Rank reported a position in CONMED (CNMD) for Q2 2019, worth a combined $2.5B — up 3.4% from $2.42B a quarter earlier.

Buyers outnumbered sellers: 39 funds opened new CNMD positions and 32 closed out — a net gain of 7 holders — while 78 added to existing stakes and 77 trimmed.

The largest buyer was Capital Research Global Investors, adding an estimated $30.3M. The largest seller was Marshall Wace, cutting an estimated $19.7M.

  • 230 institutional investors held CONMED (CNMD) as of Q2 2019, up from 226 in Q1 2019.
  • Funds reported $2.5B of CONMED stock for Q2 2019, up 3.4% quarter-over-quarter.
  • 39 funds opened new CONMED positions in Q2 2019 and 32 closed out, a net change of +7 holders.
  • The largest CONMED buyer in Q2 2019 was Capital Research Global Investors, an estimated $30.3M added.
  • The largest CONMED seller in Q2 2019 was Marshall Wace, an estimated $19.7M sold.

Based on aggregated 13F filings for Q2 2019.